AR052880A1 - Metodo para tratar dolor visceral - Google Patents
Metodo para tratar dolor visceralInfo
- Publication number
- AR052880A1 AR052880A1 ARP060100177A ARP060100177A AR052880A1 AR 052880 A1 AR052880 A1 AR 052880A1 AR P060100177 A ARP060100177 A AR P060100177A AR P060100177 A ARP060100177 A AR P060100177A AR 052880 A1 AR052880 A1 AR 052880A1
- Authority
- AR
- Argentina
- Prior art keywords
- visceral pain
- treat visceral
- administering
- oxycodone
- dose
- Prior art date
Links
- 208000009935 visceral pain Diseases 0.000 title abstract 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 229960002085 oxycodone Drugs 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229940051877 other opioids in atc Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64549005P | 2005-01-18 | 2005-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052880A1 true AR052880A1 (es) | 2007-04-11 |
Family
ID=35871217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100177A AR052880A1 (es) | 2005-01-18 | 2006-01-18 | Metodo para tratar dolor visceral |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20080200493A1 (enExample) |
| EP (1) | EP1838318B1 (enExample) |
| JP (1) | JP5049139B2 (enExample) |
| KR (10) | KR20140091782A (enExample) |
| CN (1) | CN101106996B (enExample) |
| AP (1) | AP2249A (enExample) |
| AR (1) | AR052880A1 (enExample) |
| AT (2) | ATE446092T1 (enExample) |
| AU (1) | AU2006207498B2 (enExample) |
| BR (1) | BRPI0606247A2 (enExample) |
| CA (1) | CA2595043C (enExample) |
| CY (1) | CY1109660T1 (enExample) |
| DE (2) | DE602006009899D1 (enExample) |
| DK (2) | DK1838318T3 (enExample) |
| EA (1) | EA013544B1 (enExample) |
| ES (1) | ES2333901T3 (enExample) |
| HR (1) | HRP20090679T1 (enExample) |
| IL (1) | IL184530A (enExample) |
| ME (1) | ME01066B (enExample) |
| MX (1) | MX2007007207A (enExample) |
| MY (1) | MY144471A (enExample) |
| NO (1) | NO338968B1 (enExample) |
| NZ (1) | NZ555852A (enExample) |
| PL (1) | PL1838318T3 (enExample) |
| PT (1) | PT1838318E (enExample) |
| RS (1) | RS51069B (enExample) |
| SI (1) | SI1838318T1 (enExample) |
| TW (1) | TWI432196B (enExample) |
| UA (1) | UA85471C2 (enExample) |
| WO (1) | WO2006077212A1 (enExample) |
| ZA (1) | ZA200705231B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2380592B1 (en) | 2005-11-14 | 2018-03-07 | Teva Pharmaceuticals International GmbH | Antagonist antibody directed against calcitonin gene-related peptide |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| ES2689322T3 (es) | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
| CN103957935B (zh) | 2011-05-20 | 2018-04-03 | 奥尔德生物控股有限责任公司 | 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途 |
| SG10201604040PA (en) | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
| JP6374789B2 (ja) | 2011-05-20 | 2018-08-15 | アルダーバイオ・ホールディングズ・エルエルシー | 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| HRP20240159T1 (hr) | 2014-03-21 | 2024-04-12 | Teva Pharmaceuticals International Gmbh | Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| AU2019383389A1 (en) | 2018-11-19 | 2021-05-06 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| JOP20210156A1 (ar) | 2019-01-08 | 2023-01-30 | H Lundbeck As | علاج إسعافي وعلاج سريع للصداع باستخدام أجسام مضادة لـ cgrp |
| AU2020202454A1 (en) | 2020-04-06 | 2021-10-21 | H. Lundbeck A/S | Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| AU725556B2 (en) * | 1996-03-25 | 2000-10-12 | Eli Lilly And Company | Method for treating pain |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US6992193B2 (en) * | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
-
2006
- 2006-01-05 TW TW095100458A patent/TWI432196B/zh not_active IP Right Cessation
- 2006-01-09 MY MYPI20060082A patent/MY144471A/en unknown
- 2006-01-17 PL PL06700652T patent/PL1838318T3/pl unknown
- 2006-01-17 DE DE602006009899T patent/DE602006009899D1/de active Active
- 2006-01-17 KR KR1020147018838A patent/KR20140091782A/ko not_active Ceased
- 2006-01-17 NZ NZ555852A patent/NZ555852A/en unknown
- 2006-01-17 RS RSP-2009/0553A patent/RS51069B/sr unknown
- 2006-01-17 DE DE202006019887U patent/DE202006019887U1/de not_active Expired - Lifetime
- 2006-01-17 AT AT06700652T patent/ATE446092T1/de active
- 2006-01-17 KR KR1020237042001A patent/KR20230170811A/ko not_active Ceased
- 2006-01-17 EA EA200701541A patent/EA013544B1/ru not_active IP Right Cessation
- 2006-01-17 SI SI200630538T patent/SI1838318T1/sl unknown
- 2006-01-17 US US11/814,020 patent/US20080200493A1/en not_active Abandoned
- 2006-01-17 CA CA2595043A patent/CA2595043C/en active Active
- 2006-01-17 UA UAA200708142A patent/UA85471C2/ru unknown
- 2006-01-17 PT PT06700652T patent/PT1838318E/pt unknown
- 2006-01-17 AP AP2007004057A patent/AP2249A/xx active
- 2006-01-17 WO PCT/EP2006/050252 patent/WO2006077212A1/en not_active Ceased
- 2006-01-17 KR KR1020207031796A patent/KR20200128451A/ko not_active Ceased
- 2006-01-17 AU AU2006207498A patent/AU2006207498B2/en active Active
- 2006-01-17 KR KR1020227041445A patent/KR20220165797A/ko not_active Ceased
- 2006-01-17 KR KR1020217034339A patent/KR20210131450A/ko not_active Ceased
- 2006-01-17 KR KR1020077018905A patent/KR20070100368A/ko not_active Ceased
- 2006-01-17 KR KR1020177004572A patent/KR20170021905A/ko not_active Ceased
- 2006-01-17 ME MEP-2009-352A patent/ME01066B/me unknown
- 2006-01-17 KR KR1020087029312A patent/KR20080106991A/ko not_active Ceased
- 2006-01-17 ES ES06700652T patent/ES2333901T3/es active Active
- 2006-01-17 DK DK06700652T patent/DK1838318T3/da active
- 2006-01-17 BR BRPI0606247-4A patent/BRPI0606247A2/pt not_active Application Discontinuation
- 2006-01-17 CN CN2006800024739A patent/CN101106996B/zh active Active
- 2006-01-17 EP EP06700652A patent/EP1838318B1/en active Active
- 2006-01-17 JP JP2007550797A patent/JP5049139B2/ja not_active Expired - Fee Related
- 2006-01-17 KR KR1020127011713A patent/KR20120089710A/ko not_active Ceased
- 2006-01-17 MX MX2007007207A patent/MX2007007207A/es active IP Right Grant
- 2006-01-17 HR HR20090679T patent/HRP20090679T1/hr unknown
- 2006-01-17 KR KR1020197035201A patent/KR20190135557A/ko not_active Ceased
- 2006-01-18 AR ARP060100177A patent/AR052880A1/es unknown
-
2007
- 2007-03-09 AT AT0014807U patent/AT9895U1/de not_active IP Right Cessation
- 2007-07-02 ZA ZA200705231A patent/ZA200705231B/xx unknown
- 2007-07-10 IL IL184530A patent/IL184530A/en active IP Right Grant
- 2007-07-24 DK DK200700207U patent/DK200700207U3/da not_active IP Right Cessation
- 2007-08-14 NO NO20074174A patent/NO338968B1/no not_active IP Right Cessation
-
2009
- 2009-12-16 CY CY20091101308T patent/CY1109660T1/el unknown
-
2014
- 2014-10-15 US US14/515,216 patent/US9271974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052880A1 (es) | Metodo para tratar dolor visceral | |
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| JO2858B1 (en) | Pharmaceutical dosage images | |
| HRP20180436T1 (hr) | Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima | |
| AR086391A1 (es) | Formas de dosificacion farmaceutica intranasales que comprenden naloxona | |
| AR058598A1 (es) | Administracion transdermica de meptazinol | |
| CL2008000606A1 (es) | Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naloxona, util para el tratamiento del dolor. | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| UA109781C2 (uk) | Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них | |
| MX2009010930A (es) | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi3k alfa. | |
| AR092820A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit | |
| CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
| CL2008000608A1 (es) | Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naltrexona, util para el tratamiento del dolor. | |
| MX370898B (es) | Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов | |
| PH12016500666A1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| WO2011109743A3 (en) | Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain | |
| GEP20125526B (en) | Drug active in neuropathic pain | |
| DE602004030048D1 (de) | Ffizienz | |
| WO2009019693A3 (en) | Analgesic effect of jasmonate derivatives | |
| EA201200319A1 (ru) | Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана | |
| AR060394A1 (es) | Composicion farmaceutica que comprende un analgesico y vitaminas | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| ATE380550T1 (de) | Synergistische kombination eines opiatanalgetikums und eines nsaid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |